Summary
BeiGene, Ltd. (ONC) announced significant updates regarding the inclusion of its key medicines on China's National Reimbursement Drug List (NRDL), effective January 1, 2022. This inclusion is crucial for market access and patient affordability, as it enables reimbursement through China's public medical insurance system at negotiated payment standards. The NRDL listing impacts Tislelizumab across five approved indications, including its use in first-line non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). Furthermore, BRUKINSA® is now covered for three indications, including Waldenström's macroglobulinemia (WM) and mantle cell lymphoma (MCL). Pamiparib, a PARP inhibitor, is also included for recurrent advanced ovarian cancer with gBRCA mutations. These developments are expected to substantially drive sales and patient uptake for BeiGene's innovative oncology portfolio within China, a critical growth market.
Key Highlights
- 1Tislelizumab now included in China's NRDL for five approved indications, including first-line NSCLC and HCC.
- 2BRUKINSA® is now listed on the NRDL for three indications, covering WM, MCL, and CLL/SLL.
- 3Pamiparib has been added to the NRDL for the treatment of recurrent advanced ovarian cancer in patients with gBRCA mutations.
- 4The NRDL inclusion effective January 1, 2022, sets specific payment standards for each drug and indication, facilitating broader patient access and reimbursement.
- 5The company also announced a separate NMPA approval for tislelizumab as a second- or third-line treatment for NSCLC on January 6, 2022.
- 6These NRDL listings are expected to be significant catalysts for revenue growth and market penetration in China.
- 7Negotiated NRDL payment standards provide a framework for affordability and widespread use of BeiGene's innovative cancer therapies.